You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
中國生物製藥(01177.HK):“利斯的明透皮貼劑”獲批上市
格隆匯 09-25 17:10

格隆匯9月25日丨中國生物製藥(01177.HK)發佈公吿,集團開發的“利斯的明透皮貼劑”(商標名:得百泰®)已獲得中國國家藥品監督管理局的上市批准,用於治療輕、中度阿爾茨海默病的症狀。這是首個獲批上市的國產利斯的明透皮貼劑。

根據披露,利斯的明是一種膽礆酯酶抑制劑,用於治療阿爾茨海默病。乙酰膽礆是一種在神經元之間傳遞信息的重要神經遞質,在與記憶和學習相關的腦區中起着關鍵作用。利斯的明通過抑制乙酰膽礆酯酶(AChE)和丁酰膽礆酯酶(BuChE)的活性,減少乙酰膽礆的降解,從而增加中樞神經系統中乙酰膽礆的水平,改善患者的認知功能。

利斯的明透皮貼劑能夠在較長時間內實現藥物持續、穩定的釋放,維持患者血藥濃度穩定,減少因藥物濃度波動而引起的副作用和藥效波動。此外,透皮給藥提升了患者的依從性,簡化了藥物管理,同時適用於睡眠中的、無反應的或無法吞嚥口服藥物的患者,為患者提供了一種更為舒適的治療選擇。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account